Warburg Research set a €108.00 ($121.35) price objective on Merck KGaA (FRA:MRK) in a research note released on Wednesday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.

MRK has been the subject of a number of other research reports. Kepler Capital Markets set a €122.00 ($137.08) price objective on Merck KGaA and gave the company a sell rating in a research note on Wednesday, July 1st. Barclays set a €90.00 ($101.12) price target on shares of Merck KGaA and gave the company a sell rating in a research report on Wednesday, June 3rd. Independent Research set a €122.00 ($137.08) price objective on shares of Merck KGaA and gave the company a buy rating in a research report on Friday, May 15th. Sanford C. Bernstein set a €115.00 ($129.21) price objective on shares of Merck KGaA and gave the company a neutral rating in a research note on Monday, June 8th. Finally, Goldman Sachs Group set a €94.00 ($105.62) target price on Merck KGaA and gave the stock a sell rating in a research note on Tuesday, July 28th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of €108.64 ($122.07).

FRA MRK opened at €108.05 ($121.40) on Wednesday. Merck KGaA has a 1-year low of €76.60 ($86.07) and a 1-year high of €115.00 ($129.21). The stock has a 50-day moving average of €107.71 and a 200-day moving average of €106.94.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: Do equity income investments outperform growth and income investments?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.